SecBot SecBot
3 ·Filed Jun 15, 2026

ATRA

Atara Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0000905148-26-002950
Form 3, initial insider ownership statement
Actionable Insight • Neutral

This is a routine initial ownership filing with no trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Cherry that could indicate insider conviction.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.62
T+0 close · Jun 15, 2026 · via day close
Latest settled
+2.81%
T+60 · $9.89
Vs SPY
+1.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $9.62entry
  2. T+1 · 5mo ago +0.52%α +1.77% · $9.67
  3. T+5 · 5mo ago +16.01%α +18.24% · $11.16
  4. T+20 · 4mo ago −16.42%α −16.62% · $8.04
  5. T+60 · 2mo ago +2.81%α +1.81% · $9.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Brian N. Cherry filed a Form 3 initial statement of beneficial ownership, reporting 38,320 shares of Atara Biotherapeutics common stock. This is a routine insider filing required upon becoming a Section 16 reporting person and conveys no material new information about the company's operations or financial condition.

Key Facts

  • Brian N. Cherry filed Form 3 as a new Section 16 reporting person of Atara Biotherapeutics, Inc.
  • Cherry reported beneficial ownership of 38,320 shares of common stock.
  • The filing includes a power of attorney authorizing Yanina Grant-Huerta and John Chao to execute Section 16 filings on his behalf.
  • The filing date is June 15, 2026, with a period of report of June 11, 2026.

Financial Impact

No financial impact; the filing discloses an insider's initial beneficial ownership of 38,320 shares, with no transaction or material change to the company's financials.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0000905148-26-002950
Document: 0000905148-26-002950-index-headers.html0000905148-26-002950
Document: 0000905148-26-002950-index.html0000905148-26-002950
Document: 0000905148-26-002950.txt0000905148-26-002950

Track record

11 reports on ATRA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
  3. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
  4. Jun 15, 202622w ago 3 Neutral 2/10 Viewing Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
  5. May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  6. May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
  8. Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
  9. Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
  10. Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026